DUBLIN, Dec. 1, 2021 /PRNewswire/ -- The "Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global pharmerging market exhibited strong growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of 10.4% during 2021-2026. Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals.
Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.
The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited. Key Questions Answered in This Report:
- How has the global pharmerging market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What is the impact of COVID-19 on global pharmerging market?
- What is the breakup of the market based on the product outlook?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the market?
- What is the structure of the global pharmerging market and who are the key players?
- What is the degree of competition in the market?
Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction4.1 Overview4.2 Key Industry Trends 5 Global Pharmerging Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Forecast 6 Market Breakup by Product6.1 Pharmaceutical 6.1.1 Market Trends6.1.2 Major Types184.108.40.206 Patented Prescription Drugs220.127.116.11 Generic Prescription Drugs18.104.22.168 OTC Drugs6.1.3 Market Forecast6.2 Healthcare 6.2.1 Market Trends6.2.2 Major Types22.214.171.124 Medical Devices126.96.36.199 Clinical Diagnosis188.8.131.52 Others6.2.3 Market Forecast 7 Market Breakup by Indication7.1 Lifestyle Diseases 7.1.1 Market Trends7.1.2 Market Forecast7.2 Cancer and Autoimmune Diseases 7.2.1 Market Trends7.2.2 Market Forecast7.3 Infectious Diseases 7.3.1 Market Trends7.3.2 Market Forecast7.4 Others 7.4.1 Market Trends7.4.2 Market Forecast 8 Market Breakup by Distribution Channel8.1 Hospitals8.1.1 Market Trends8.1.2 Market Forecast8.2 Retail Pharmacies8.2.1 Market Trends8.2.2 Market Forecast8.3 Online Stores 8.3.1 Market Trends8.3.2 Market Forecast8.4 Others 8.4.1 Market Trends8.4.2 Market Forecast 9 Market Breakup by Country 10 SWOT Analysis10.1 Overview10.2 Strengths10.3 Weaknesses10.4 Opportunities10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis12.1 Overview12.2 Bargaining Power of Buyers12.3 Bargaining Power of Suppliers12.4 Degree of Competition12.5 Threat of New Entrants12.6 Threat of Substitutes 13 Competitive Landscape13.1 Market Structure13.2 Key Players13.3 Profiles of Key Players13.3.1 Sanofi S.A.184.108.40.206 Company Overview220.127.116.11 Product Portfolio 18.104.22.168 Financials22.214.171.124 SWOT Analysis13.3.2 Pfizer Inc.126.96.36.199 Company Overview188.8.131.52 Product Portfolio 184.108.40.206 Financials220.127.116.11 SWOT Analysis13.3.3 AstraZeneca Plc.18.104.22.168 Company Overview22.214.171.124 Product Portfolio 126.96.36.199 Financials188.8.131.52 SWOT Analysis13.3.4 GlaxoSmithKline Plc.184.108.40.206 Company Overview220.127.116.11 Product Portfolio18.104.22.168 Financials22.214.171.124 SWOT Analysis13.3.5 F. Hoffmann-La Roche AG (Roche AG)126.96.36.199 Company Overview188.8.131.52 Product Portfolio 184.108.40.206 Financials220.127.116.11 SWOT Analysis13.3.6 Eli Lilly and Company18.104.22.168 Company Overview22.214.171.124 Product Portfolio 126.96.36.199 Financials188.8.131.52 SWOT Analysis13.3.7 Johnson & Johnson184.108.40.206 Company Overview220.127.116.11 Product Portfolio 18.104.22.168 Financials22.214.171.124 SWOT Analysis13.3.8 Abbott Laboratories126.96.36.199 Company Overview188.8.131.52 Product Portfolio 184.108.40.206 Financials220.127.116.11 SWOT Analysis13.3.9 Novartis AG18.104.22.168 Company Overview22.214.171.124 Product Portfolio 126.96.36.199 Financials188.8.131.52 SWOT Analysis 13.3.10 Teva Pharmaceutical Limited184.108.40.206 Company Overview220.127.116.11 Product Portfolio 18.104.22.168 Financial22.214.171.124 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/hgr7du
Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets